Literature DB >> 21269735

Vaccine-related varicella-zoster rash in a hospitalized immunocompetent patient.

Paul Bernstein1, Yoko Furuya, Sharon Steinberg, Brian Scully, Philip Larussa, Anne A Gershon.   

Abstract

An immunocompetent health care worker with no known history of varicella-zoster virus (VZV) disease was exposed to a patient with herpes zoster and was immunized 2 days later. Twenty-seven days after receiving the varicella vaccine, while hospitalized, she developed a disseminated rash. This exposure and subsequent development of symptoms posed infection control challenges. A polymerase chain reaction analysis of her vesicular fluid was positive for vaccine-type VZV, and a blood specimen collected before vaccination demonstrated a positive VZV titer by the fluorescent antibody to membrane antigen test. To the best of our knowledge, there have been no previous reports of an immunocompetent seropositive person developing vaccine-type VZV after receiving the vaccine.
Copyright © 2011 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269735      PMCID: PMC5381803          DOI: 10.1016/j.ajic.2010.06.027

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  14 in total

Review 1.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers.

Authors:  L Saiman; P LaRussa; S P Steinberg; J Zhou; K Baron; S Whittier; P Della-Latta; A A Gershon
Journal:  Infect Control Hosp Epidemiol       Date:  2001-05       Impact factor: 3.254

3.  Hospital experience with varicella-zoster virus.

Authors:  K Krasinski; R S Holzman; R LaCouture; A Florman
Journal:  Infect Control       Date:  1986-06

4.  Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen.

Authors:  A Sauerbrei; P Wutzler
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

5.  Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group.

Authors:  M Tsolia; A A Gershon; S P Steinberg; L Gelb
Journal:  J Pediatr       Date:  1990-02       Impact factor: 4.406

Review 6.  Prospects for use of a varicella vaccine in adults.

Authors:  I R Hardy; A A Gershon
Journal:  Infect Dis Clin North Am       Date:  1990-03       Impact factor: 5.982

7.  Susceptibility to varicella zoster virus infection in health care workers.

Authors:  J Gallagher; B Quaid; B Cryan
Journal:  Occup Med (Lond)       Date:  1996-08       Impact factor: 1.611

8.  Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.

Authors:  P LaRussa; O Lungu; I Hardy; A Gershon; S P Steinberg; S Silverstein
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  Immunization of healthy adults with live attenuated varicella vaccine.

Authors:  A A Gershon; S P Steinberg; P LaRussa; A Ferrara; M Hammerschlag; L Gelb
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

10.  Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Mona Marin; Dalya Güris; Sandra S Chaves; Scott Schmid; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2007-06-22
View more
  5 in total

Review 1.  Vaccination of healthcare workers: A review.

Authors:  Skerdi Haviari; Thomas Bénet; Mitra Saadatian-Elahi; Philippe André; Pierre Loulergue; Philippe Vanhems
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data.

Authors:  G S Goldman; P G King
Journal:  Vaccine       Date:  2012-06-01       Impact factor: 3.641

3.  Disseminated herpes zoster ophthalmicus in an immunocompetent 8-year old boy.

Authors:  Regina Eziuka Oladokun; Chikodili N Olomukoro; Adewale B Owa
Journal:  Clin Pract       Date:  2013-05-20

Review 4.  Biologically hazardous agents at work and efforts to protect workers' health: a review of recent reports.

Authors:  Kyung-Taek Rim; Cheol-Hong Lim
Journal:  Saf Health Work       Date:  2014-04-05

5.  Brief communication: A 61-year-old woman with vesicular eruption after varicella zoster vaccination.

Authors:  Karen Ganacias; Sarah Spriet; Taylor A Banks
Journal:  Allergy Rhinol (Providence)       Date:  2016-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.